Ribapak and Acute kidney failure - a phase IV clinical study of FDA data

Summary:

Acute kidney failure is reported as a side effect among people who take Ribapak (ribavirin), especially for people who are male, 50-59 old, have been taking the drug for 6 - 12 months also take Peg-Intron, and have Hepatitis c.

The phase IV clinical study analyzes which people have Acute kidney failure when taking Ribapak. It is created by eHealthMe based on reports of 3,390 people who have side effects when taking Ribapak from the FDA, and is updated regularly.

What is Ribapak?

Ribapak has active ingredients of ribavirin. eHealthMe is studying from 3,392 Ribapak users. Check the latest studies of Ribapak.

What is Acute kidney failure?

Acute kidney failure is found to be associated with 2,836 drugs and 4,496 conditions by eHealthMe. Check the latest studies of Acute kidney failure.

On Aug, 07, 2026

3,390 people reported to have side effects when taking Ribapak.
Among them, 12 people (0.35%) have Acute kidney failure.

Could Ribapak cause Acute kidney failure?

Among these 12 people:

How long have people been on Ribapak when they have Acute kidney failure? *

What is the gender of people who have Acute kidney failure when taking Ribapak? *

female: 41.67 %
male: 58.33 %

What is the age of people who have Acute kidney failure when taking Ribapak? *

What are other drugs people take besides Ribapak? *

What are other side effects people have besides Acute kidney failure? *

Weakness: 4 people, 33.33%
Anaemia (lack of blood): 4 people, 33.33%
Fatigue (feeling of tiredness): 3 people, 25.00%
Mental Status Changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation): 3 people, 25.00%
Fainting (loss of consciousness and postural tone): 3 people, 25.00%
Memory Loss: 3 people, 25.00%
Hyponatremia (abnormally low level of sodium in the blood; associated with dehydration): 3 people, 25.00%
Abdominal Distension: 2 people, 16.67%
Depression: 2 people, 16.67%
Nausea And Vomiting: 2 people, 16.67%

What are the existing conditions these people have? *

Hepatitis C: 10 people, 83.33%
Oedema (fluid collection in tissue): 1 person, 8.33%
Insomnia (sleeplessness): 1 person, 8.33%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 8.33%
Bipolar Disorder (mood disorder): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Ribapak and have Acute kidney failure?

- Check whether Acute kidney failure is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ribapak:

Ribapak (3,392 reports)

Browse all side effects of Ribapak:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Acute kidney failure:

Acute kidney failure (2,836 drugs)

Browse all the conditions that are associated with Acute kidney failure:

Acute kidney failure (4,496 conditions)

Related publications that referenced our studies

Lin SY, Lin CL, Ju SW, Wang IK, Lin CC, Lin CH, Hsu WH, Liang JA, "Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study", PloS one, 2017 Mar .
Lin SY, Lin CL, Ju SW, Wang IK, Lin CC, Lin CH, Hsu WH, Liang JA, "Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study", PloS one, 2017 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on ribavirin (the active ingredients of Ribapak) and Ribapak (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.